Premium
Preconditioned neurons with NaB and nicorandil, a favorable source for stroke cell therapy
Author(s) -
Hosseini Seyed Mojtaba,
Ziaee Seyyed Mohyeddin,
Haider Khawaja Husnanin,
Karimi Aliashghar,
Tabeshmehr Parisa,
Abbasi Zahra
Publication year - 2018
Publication title -
journal of cellular biochemistry
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.028
H-Index - 165
eISSN - 1097-4644
pISSN - 0730-2312
DOI - 10.1002/jcb.27372
Subject(s) - proinflammatory cytokine , neural stem cell , neuroinflammation , chemistry , nestin , medicine , cancer research , pharmacology , stem cell , biology , inflammation , immunology , microbiology and biotechnology
Poor survival of stem cells in the harsh microenvironment at the site of stroke, especially during acute phase of injury, remains a serious obstacle to achieve the desired prognosis. We hypothesized that combined treatment of neural stem cells (NSCs) with small molecules would precondition them to become robust and survive better as compared with the native nonpreconditioned cells. Mouse ganglionic NSCs were isolated, cultured, and characterized. The cells were preconditioned by treatment with sodium butyrate (NaB) and nicorandil (Nico) and transplanted in an experimentally induced stroke model. Sham‐operated animals without treatment or animals with experimental stroke treated with basal medium, native NSCs, NSCs preconditioned with NaB or Nico alone were used as controls. The tissue samples and cells with different treatments were used to measure brain‐tissue–derived neurotrophic factor (BDNF) level and the activity of phosphatidylinositol‐3 kinase (PI3K), apurinic/apyrimidinic endonuclease 1 (APE1), and nuclear factor‐κB (NF‐κB) p50 both in vitro and in vivo, respectively. Additionally, survival of the cells and recovery indices for stroke were studied. The combined treatment with NaB + Nico resulted in increased BDNF level and higher PI3K, APE1, and the downstream NF‐κB activation, which were blocked by pretreatment with their respective inhibitors. Donor cell survival increased postengraftment as assessed by 5‐bromo‐2′‐deoxyuridine immunostaining and reduced Terminal deoxynucleotide transferase dUTP Nick End Labeling positivity at the site of engraftment. There was reduction in proinflammatory cytokines and infiltration of both GFAP + and CD68 + at the injury site. There was reduction in the infarct size and neurological function was preserved in the preconditioned cell treatment group. Our preconditioning approach with small molecules effectively improved the survival as well as functionality of NSCs.